WE CLAIM:

1. A method for the synergistic treatment of cancer comprising administering to a mammal in need thereof a therapeutically effective amount of an EGFR inhibitor in combination with a therapeutically effective amount of an IGF1R inhibitor in amounts sufficient to achieve synergistic effects.

2. The method according to claim 1 wherein said EGFR inhibitor is cetuximab.

3. The method according to claim 1 wherein said EGFR inhibitor is erlotinib.

4. The method according to claim 1 wherein said EGFR inhibitor is gefitinib.

5. The method according to claim 1 wherein said EGFR inhibitor is EKB-569.

6. The method according to claim 1 where in said EGFR inhibitor is ABX-EGF.

7. The method according to claim 1 wherein said IGF1R inhibitor has the following formula I



I

its enantiomers, diastereomers, pharmaceutically acceptable salts, hydrates, prodrugs and solvates thereof;

wherein

X is N, C_1-C_3 alkyl, or a direct bond;

Y is O or S ;

W is N, C, O, or S; provided that if W is O or S, R^9 is absent;

R^1 is H, alkyl, or alkoxy;

R^2 and R^9 are independently H or alkyl;

R^3 is H, C_{1-6} alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, amino, $-OR^{60}$, $-NO_2$, -OH, $-SR^{60}$, $-NR^{60}R^{61}$, -CN,$-C(O)R^{60}$, $-CO_2R^{60}$, $-CONR^{60}R^{61}$, $OCONR^{60}R^{61}$, $-NR^{62}CONR^{60}R^{61}$, $-NR^{60}SO_2R^{61}$, $-SO_2NR^{60}R^{61}$, $-SO_2R^{63}$, $-C(NR^{62})NR^{60}R^{61}$, $-C(NH^{62})$-morpholine, aryl, heteroaryl, $-(CH_2)_nC(O)_2-R^{60}$, $-NR^{60}R^{61}$ $-(CH_2)_nOR^{60}$, $-(CH_2)_nNR^{60}R^{61}$, $-(CH_2)_nSR^{60}$, $-(CH_2)_n$ aryl, $-(CH_2)_n$ heteroaryl, or $-(CH_2)_n$ heterocycloalkyl, wherein n is 1 to 3:

R^4 is H, halo, alkyl or haloalkyl;

R^5 is H, alkyl, halo, or aryl;

R^6, R^7, and R^8 are each independently -NH-Z-aryl or -NH-Z-heteroaryl wherein Z is $C_1 - C_4$ alkyl, alkenyl, or alkynyl; Z optionally having one or more hydroxy, thiol, alkoxy, thioalkoxy, amino, halo, $NR^{60}SO_2R^{61}$ groups; Z optionally incorporating one or more groups selected from the group consisting of CO, CNOH, $CNOR^{60}$, $CNNR^{60}$, $CNNCOR^{60}$ and $CNNSO_2R^{60}$;

R^{60}, R^{61}, R^{62}, and R^{63} are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl, and alkyl-R^{25};

R^{25} is hydrogen, alkenyl, hydroxy, thiol, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, aryl, heteroaryl, cyano, halo, sulfoxy, sulfonyl, $-NR^{30}COOR^{31}$, $-NR^{30}C(O)R^{31}$, $-NR^{30}SO_2R^{31}$, $-C(O)NR^{30}R^{31}$, heteroaryl or heterocycloalkyl; and

R^{30} and R^{31} are, independently, hydrogen, alkyl, or cycloalkyl.

8. The method of claim 6 wherein R^3 is an optionally substituted morpholine, thiomorpholine, sulfoxymorpholine, sulfonylmorpholine, or homomorpholine.

9. The method according to claim 6 wherein R^3 is a substituted or unsubstituted piperazine or piperadine.

10. The method according to claim 6 wherein R^6 is -NH-Z-aryl, or -NH-Z-heteroaryl.

11. The method of claim 9 wherein said aryl is a substituted or unsubstituted phenyl.

12. The method of claim 9 wherein said heteroaryl is a substituted or unsubstituted pyridinyl, imidazolyl, pyrazolyl, pyrrolyl or triazolyl.

13. The method of claim 1 wherein the EGFR inhibitor is cetuximab and the IGF1R inhibitor is selected from the group consisting of:
(±)-4-[2-(3-Chloro-4-fluoro-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one;
(*S*)-4-[2-(3-Fluoro-phenyl)-1-hydroxymethyl-ethylamino]-3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one;
(±)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one;
(S)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1 H-pyridin-2-one;
(S)-2-[4-(2-{4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-2-oxo-1,2-dihydro-pyridin-3-yl}-7-methyl-3H-benzoimidazol-5-yl)-piperazin-1-yl]-acetamide Bis hydrochloride;
(S)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-{4-methyl-6-[4-(2-methylsulfanyl-ethyl)-piperazin-1-yl]-1H-benzoimidazol-2-yl}-1H-pyridin-2-one bis hydrochloride;
(S)4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-[4-methyl-6-(3R-methyl-piperazin-1-yl)-1H-benzoimidazol-2-yl]-1H-pyridin-2-one bis hydrochloride; and
(S)-4-[2-(3-Chloro-phenyl)-2-methoxy-ethylamino]-3-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-4-methyl-1H-benzimidazol-2-yl}-1H-pyridin-2-one.